Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

被引：0
|
作者：
Peer, Avivit
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Kovel, Svetlana
Sella, Avishay
Neumann, Avivit
Boursi, Ben
Berger, Raanan
Carducci, Michael Anthony
Keizman, Daniel
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[6] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[7] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Chaim Sheba Med Ctr, Ramat Gan, Israel
[10] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Sidney Kimmel Comprehens Canc, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET)
    Raymond, E.
    Niccoli, P.
    Raoul, J.
    Bang, Y.
    Borbath, I.
    Lombard-Bohas, C.
    Valle, J. W.
    Metrakos, P.
    Smith, D.
    Vinik, A.
    Chen, J.
    Hoersch, D.
    Castellano, D. E.
    Kennecke, H. F.
    Picus, J.
    Van Hazel, G.
    Lu, D.
    Chao, R. C.
    Patyna, S.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC)
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BJU INTERNATIONAL, 2012, 109 : 8 - 8
  • [13] Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S98 - S99
  • [14] Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
    Santoni, Matteo
    Porta, Camillo
    Procopio, Giuseppe
    Cerbone, Linda
    Basso, Umberto
    De Giorgi, Ugo
    Rizzo, Mimma
    Ortega, Cinzia
    Massari, Francesco
    Iacovelli, Roberto
    di Lorenzo, Giuseppe
    Milella, Michele
    Sabbatini, Roberto
    Atzori, Francesco
    De Vivo, Rocco
    Berardi, Rossana
    Santini, Daniele
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [15] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [17] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [18] RELATIONSHIP BETWEEN PROGRESSION-FREE (PFS) AND OVERALL SURVIVAL (OS) IN I-LINE RANDOMIZED CLINICAL TRIALS (RCT) FOR ADVANCED RENAL CELL CARCINOMA (RCC): CORRELATION AND POWER ANALYSIS
    Bria, E.
    Massari, F.
    Maines, F.
    Bonomi, M.
    Porta, C.
    Bracarda, S.
    Cognetti, F.
    Giannarelli, D.
    Tortora, G.
    Milella, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 273 - 273
  • [19] Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial.
    Wheatley, Keith
    Kadir, Bryar
    Khan, Maria
    Fenwick, Nicola
    Gaspar, Nathalie
    Kanerva, Jukka
    Kuehne, Thomas
    Longhi, Alessandra
    Mata, Cristina
    Phillips, Marianne
    Hall, Kirsten
    Safwat, Akmal
    Morales, Claudia Valverde
    Westwood, Andrew J.
    Winstanley, Mark
    Evans, Abigail
    Strauss, Sandra J.
    Dirksen, Uta
    Whelan, Jeremy
    McCabe, Martin G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [20] Association of a deep learning system with progression-free survival (PFS) in patients with renal cell carcinoma (RCC) treated with immune checkpoint blockades (ICBs)
    Xiao, Jun
    Wang, Xianyun
    Liu, Yixun
    Hu, Xuechun
    Zhang, Yiqun
    Wang, Xiaohui
    Hu, Nan
    Yang, Chunyan
    Duan, Xiaohong
    Pei, Zhihua
    Wang, Dongliang
    Zhou, Qiming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345